Corrigendum to Context-dependent function of the deubiquitinating enzyme USP9X in pancreatic ductal adenocarcinoma (Cancer Biology and Therapy, 15, 8, 2014 (1042-1052), DOI 10.4161/cbt.29182);Context-dependent function of the deubiquitinating enzyme USP9X in pancreatic ductal adenocarcinoma

Cancer Biology and Therapy

Volumn 15, Issue 8, 2014, Pages 1042-1052

  Cox, Jesse L ^a   Wilder, Phillip J ^a   Wuebben, Erin L ^a   Ouellette, Michel M ^a   Hollingsworth, Michael A ^a   Rizzino, Angie ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Deubiquitinating protease; KRAS; Oncogene; Pancreatic ductal adenocarcinoma; Tumor suppressor gene 10.4161 cbt.29182; USP9X; WP1130

Indexed keywords

DEUBIQUITINASE; DOXYCYCLINE; PROTEINASE INHIBITOR; SHORT HAIRPIN RNA; UBIQUITIN SPECIFIC PEPTIDASE 9X; UNCLASSIFIED DRUG; CYANOACRYLATE DERIVATIVE; DEGRASYN; ITCH PROTEIN, HUMAN; NITRILE; PYRIDINE DERIVATIVE; REPRESSOR PROTEIN; UBIQUITIN PROTEIN LIGASE; UBIQUITIN THIOLESTERASE; USP9X PROTEIN, HUMAN;

ADVANCED CANCER; ANCHORAGE INDEPENDENT GROWTH; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER DIAGNOSIS; CARCINOGENICITY; CELL CYCLE; CELL PROLIFERATION; CELL TRANSFORMATION; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; GENE SEQUENCE; GENE SILENCING; MOUSE; MTT ASSAY; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREATIC CANCER CELL LINE; PROTEIN DEPLETION; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING; DRUG EFFECTS; GENETICS; HUMAN; METABOLISM; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; TUMOR CELL LINE; TUMOR INVASION; UBIQUITINATION;

CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CELL PROLIFERATION; CYANOACRYLATES; HUMANS; NEOPLASM INVASIVENESS; NITRILES; PANCREATIC NEOPLASMS; PROTEASE INHIBITORS; PYRIDINES; REPRESSOR PROTEINS; UBIQUITIN THIOLESTERASE; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION;

EID: 84905495804     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.1080/15384047.2016.1153924     Document Type: Erratum

References (46)

1. Schwickart M, Huang X, Lill JR, Liu J, Ferrando R, French DM, Maecker H, O'Rourke K, Bazan F, Eastham-Anderson J, et al. Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature 2010; 463:103-7; PMID:20023629; http://dx.doi.org/10.1038/nature08646
2. Xie Y, Avello M, Schirle M, McWhinnie E, Feng Y, Bric-Furlong E, Wilson C, Nathans R, Zhang J, Kirschner MW, et al. Deubiquitinase FAM/USP9X interacts with the E3 ubiquitin ligase SMURF1 protein and protects it from ligase activity-dependent self-degradation. J Biol Chem 2013; 288:2976-85; PMID:23184937; http://dx.doi.org/10.1074/jbc.M112.430066
3. Harris DR, Mims A, Bunz F. Genetic disruption of USP9X sensitizes colorectal cancer cells to 5-fluorouracil. Cancer Biol Ther 2012; 13:1319-24; PMID:22895071; http://dx.doi.org/10.4161/cbt.21792
4. Wang S, Kollipara RK, Srivastava N, Li R, Ravindranathan P, Hernandez E, Freeman E, Humphries CG, Kapur P, Lotan Y, et al. Ablation of the oncogenic transcription factor ERG by deubiquitinase inhibition in prostate cancer. Proc Natl Acad Sci U S A 2014; 111:4251-6; PMID:24591637; http://dx.doi.org/10.1073/ pnas.1322198111
5. Cox JL, Wilder PJ, Gilmore JM, Wuebben EL, Washburn MP, Rizzino A. The SOX2-interactome in brain cancer cells identifies the requirement of MSI2 and USP9X for the growth of brain tumor cells. PLoS One 2013; 8:e62857; PMID:23667531; http://dx.doi.org/10.1371/journal.pone.0062857
6. Mann KM, Ward JM, Yew CCK, Kovochich A, Dawson DW, Black MA, Brett BT, Sheetz TE, Dupuy AJ, Chang DK, et al.; Australian Pancreatic Cancer Genome Initiative. Sleeping Beauty mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinoma. Proc Natl Acad Sci U S A 2012; 109:5934-41; PMID:22421440; http://dx.doi.org/10.1073/pnas.1202490109
7. Pérez-Mancera PA, Rust AG, van der Weyden L, Kristiansen G, Li A, Sarver AL, Silverstein KAT, Grützmann R, Aust D, Rümmele P, et al.; Australian Pancreatic Cancer Genome Initiative. The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Nature 2012; 486:266-70; PMID:22699621
8. Dalal BI, Keown PA, Greenberg AH. Immunocytochemical localization of secreted transforming growth factor-beta 1 to the advancing edges of primary tumors and to lymph node metastases of human mammary carcinoma. Am J Pathol 1993; 143:381-9; PMID:8393616
9. Siegel PM, Shu W, Cardiff RD, Muller WJ, Massagué J. Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proc Natl Acad Sci U S A 2003; 100:8430-5; PMID:12808151; http://dx.doi.org/10.1073/pnas.0932636100
10. Tian F, Byfield SD, Parks WT, Stuelten CH, Nemani D, Zhang YE, Roberts AB. Smad-binding defective mutant of transforming growth factor beta type I receptor enhances tumorigenesis but suppresses metastasis of breast cancer cell lines. Cancer Res 2004; 64:4523-30; PMID:15231662; http://dx.doi.org/10.1158/ 0008-5472.CAN-04-0030
11. Kita K, Saito S, Morioka CY, Watanabe A. Growth inhibition of human pancreatic cancer cell lines by anti-sense oligonucleotides specific to mutated K-ras genes. Int J Cancer 1999; 80:553-8; PMID:9935156; http://dx.doi.org/10. 1002/(SICI) 1097-0215(19990209)80:4〈553::AID-IJC12〉3.0.CO;2-6
12. Wiebe MS, Traktman P. Poxviral B1 kinase overcomes barrier to autointegration factor, a host defense against virus replication. Cell Host Microbe 2007; 1:187-97; PMID:18005698; http://dx.doi.org/10.1016/j.chom.2007.03. 007
13. Chen Y, Shi L, Zhang L, Li R, Liang J, Yu W, Sun L, Yang X, Wang Y, Zhang Y, et al. The molecular mechanism governing the oncogenic potential of SOX2 in breast cancer. J Biol Chem 2008; 283:17969-78; PMID:18456656; http://dx.doi.org/10.1074/jbc.M802917200
14. Jia X, Li X, Xu Y, Zhang S, Mou W, Liu Y, Liu Y, Lv D, Liu C-H, Tan X, et al. SOX2 promotes tumorigenesis and increases the anti-apoptotic property of human prostate cancer cell. J Mol Cell Biol 2011; 3:230-8; PMID:21415100; http://dx.doi.org/10.1093/jmcb/mjr002
15. Nakatsugawa M, Takahashi A, Hirohashi Y, Torigoe T, Inoda S, Murase M, Asanuma H, Tamura Y, Morita R, Michifuri Y, et al. SOX2 is overexpressed in stem-like cells of human lung adenocarcinoma and augments the tumorigenicity. Lab Invest 2011; 91:1796-804; PMID:21931300; http://dx.doi.org/10.1038/ labinvest.2011.140
16. Kopp JL, Ormsbee BD, Desler M, Rizzino A. Small increases in the level of Sox2 trigger the differentiation of mouse embryonic stem cells. Stem Cells 2008; 26:903-11; PMID:18238855; http://dx.doi.org/10.1634/stemcells.2007-0951
17. Cox JL, Wilder PJ, Desler M, Rizzino A. Elevating SOX2 levels deleteriously affects the growth of medulloblastoma and glioblastoma cells. PLoS One 2012; 7:e44087; PMID:22937156; http://dx.doi.org/10.1371/journal.pone. 0044087
18. Carney DN, Gazdar AF, Minna JD. Positive correlation between histological tumor involvement and generation of tumor cell colonies in agarose in specimens taken directly from patients with small-cell carcinoma of the lung. Cancer Res 1980; 40:1820-3; PMID:6245805
19. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF, Simeone DM. Identification of pancreatic cancer stem cells. Cancer Res 2007; 67:1030-7; PMID:17283135; http://dx.doi.org/10.1158/0008-5472.CAN-06-2030
20. Mouchantaf R, Azakir BA, McPherson PS, Millard SM, Wood SA, Angers A. The ubiquitin ligase itch is auto-ubiquitylated in vivo and in vitro but is protected from degradation by interacting with the deubiquitylating enzyme FAM/USP9X. J Biol Chem 2006; 281:38738-47; PMID:17038327; http://dx.doi.org/10. 1074/jbc.M605959200
21. Campbell PM, Groehler AL, Lee KM, Ouellette MM, Khazak V, Der CJ. K-Ras promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3-kinase signaling. Cancer Res 2007; 67:2098-106; PMID:17332339; http://dx.doi.org/10.1158/0008-5472.CAN-06-3752
22. Rolén U, Kobzeva V, Gasparjan N, Ovaa H, Winberg G, Kisseljov F, Masucci MG. Activity profiling of deubiquitinating enzymes in cervical carcinoma biopsies and cell lines. Mol Carcinog 2006; 45:260-9; PMID:16402389; http://dx.doi.org/10.1002/mc.20177
23. Kapuria V, Peterson LF, Fang D, Bornmann WG, Talpaz M, Donato NJ. Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis. Cancer Res 2010; 70:9265-76; PMID:21045142; http://dx.doi.org/10.1158/0008-5472.CAN-10-1530
24. Sun H, Kapuria V, Peterson LF, Fang D, Bornmann WG, Bartholomeusz G, Talpaz M, Donato NJ. Bcr-Abl ubiquitination and Usp9x inhibition block kinase signaling and promote CML cell apoptosis. Blood 2011; 117:3151-62; PMID:21248063; http://dx.doi.org/10.1182/blood-2010-03-276477
25. Pham LV, Tamayo AT, Li C, Bornmann W, Priebe W, Ford RJ. Degrasyn potentiates the antitumor effects of bortezomib in mantle cell lymphoma cells in vitro and in vivo: therapeutic implications. Mol Cancer Ther 2010; 9:2026-36; PMID:20606045; http://dx.doi.org/10.1158/1535-7163.MCT-10-0238
26. Dasgupta S, Jang JS, Shao C, Mukhopadhyay ND, Sokhi UK, Das SK, Brait M, Talbot C, Yung RC, Begum S, et al. SH3GL2 is frequently deleted in non-small cell lung cancer and downregulates tumor growth by modulating EGFR signaling. J Mol Med (Berl) 2013; 91:381-93; PMID:22968441; http://dx.doi.org/10.1007/s00109- 012-0955-3
27. Deng S, Zhou H, Xiong R, Lu Y, Yan D, Xing T, Dong L, Tang E, Yang H. Over-expression of genes and proteins of ubiquitin specific peptidases (USPs) and proteasome subunits (PSs) in breast cancer tissue observed by the methods of RFDD-PCR and proteomics. Breast Cancer Res Treat 2007; 104:21-30; PMID:17004105; http://dx.doi.org/10.1007/s10549-006-9393-7
28. Peddaboina C, Jupiter D, Fletcher S, Yap JL, Rai A, Tobin RP, Jiang W, Rascoe P, Rogers MKN, Smythe WR, et al. The downregulation of Mcl-1 via USP9X inhibition sensitizes solid tumors to Bcl-xl inhibition. BMC Cancer 2012; 12:541; PMID:23171055; http://dx.doi.org/10.1186/1471-2407-12-541
29. Peng J, Hu Q, Liu W, He X, Cui L, Chen X, Yang M, Liu H, Wei W, Liu S, et al. USP9X expression correlates with tumor progression and poor prognosis in esophageal squamous cell carcinoma. Diagn Pathol 2013; 8:177; PMID:24152793; http://dx.doi.org/10.1186/1746-1596-8-177
30. Herreros-Villanueva M, Zhang J-S, Koenig A, Abel EV, Smyrk TC, Bamlet WR, de Narvajas AA-M, Gomez TS, Simeone DM, Bujanda L, et al. SOX2 promotes dedifferentiation and imparts stem cell-like features to pancreatic cancer cells. Oncogenesis 2013; 2:e61; PMID:23917223; http://dx.doi.org/10.1038/oncsis. 2013.23
31. Murray RZ, Jolly LA, Wood SA. The FAM deubiquitylating enzyme localizes to multiple points of protein trafficking in epithelia, where it associates with E-cadherin and beta-catenin. Mol Biol Cell 2004; 15:1591-9; PMID:14742711; http://dx.doi.org/10.1091/mbc.E03-08-0630
32. Taya S, Yamamoto T, Kanai-Azuma M, Wood SA, Kaibuchi K. The deubiquitinating enzyme Fam interacts with and stabilizes beta-catenin. Genes Cells 1999; 4:757-67; PMID:10620020; http://dx.doi.org/10.1046/j.1365-2443.1999. 00297.x
33. Théard D, Labarrade F, Partisani M, Milanini J, Sakagami H, Fon EA, Wood SA, Franco M, Luton F. USP9x-mediated deubiquitination of EFA6 regulates de novo tight junction assembly. EMBO J 2010; 29:1499-509; PMID:20339350; http://dx.doi.org/10.1038/emboj.2010.46
34. Gao Z, Cox JL, Gilmore JM, Ormsbee BD, Mallanna SK, Washburn MP, Rizzino A. Determination of protein interactome of transcription factor Sox2 in embryonic stem cells engineered for inducible expression of four reprogramming factors. J Biol Chem 2012; 287:11384-97; PMID:22334693; http://dx.doi.org/10. 1074/jbc.M111.320143
35. Sanada Y, Yoshida K, Ohara M, Oeda M, Konishi K, Tsutani Y. Histopathologic evaluation of stepwise progression of pancreatic carcinoma with immunohistochemical analysis of gastric epithelial transcription factor SOX2: comparison of expression patterns between invasive components and cancerous or nonneoplastic intraductal components. Pancreas 2006; 32:164-70; PMID:16552336; http://dx.doi.org/10.1097/01.mpa.0000202947.80117.a0
36. Collisson EA, Sadanandam A, Olson P, Gibb WJ, Truitt M, Gu S, Cooc J, Weinkle J, Kim GE, Jakkula L, et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med 2011; 17:500-3; PMID:21460848; http://dx.doi.org/10.1038/nm.2344
37. Trivigno D, Essmann F, Huber SM, Rudner J. Deubiquitinase USP9x confers radioresistance through stabilization of Mcl-1. Neoplasia 2012; 14:893-904; PMID:23097624
38. Colland F, Formstecher E, Jacq X, Reverdy C, Planquette C, Conrath S, Trouplin V, Bianchi J, Aushev VN, Camonis J, et al. Small-molecule inhibitor of USP7/HAUSP ubiquitin protease stabilizes and activates p53 in cells. Mol Cancer Ther 2009; 8:2286-95; PMID:19671755; http://dx.doi.org/10.1158/1535-7163.MCT-09- 0097
39. Lee KM, Nguyen C, Ulrich AB, Pour PM, Ouellette MM. Immortalization with telomerase of the Nestin-positive cells of the human pancreas. Biochem Biophys Res Commun 2003; 301:1038-44; PMID:12589817; http://dx.doi.org/10.1016/S0006- 291X(03)00086-X
40. Lee J, Jang K-T, Ki C-S, Lim T, Park YS, Lim HY, Choi D-W, Kang WK, Park K, Park JO. Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma. Cancer 2007; 109:1561-9; PMID:17354229; http://dx.doi.org/10. 1002/cncr.22559
41. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65:55-63; PMID:6606682; http://dx.doi.org/10.1016/0022-1759(83)90303-4
42. Hansen MB, Nielsen SE, Berg K. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods 1989; 119:203-10; PMID:2470825; http://dx.doi.org/10.1016/0022-1759(89) 90397-9
43. Cox JL, Mallanna SK, Ormsbee BD, Desler M, Wiebe MS, Rizzino A. Banf1 is required to maintain the selfrenewal of both mouse and human embryonic stem cells. J Cell Sci 2011; 124:2654-65; PMID:21750191; http://dx.doi.org/10.1242/ jcs.083238
44. Mallanna SK, Ormsbee BD, Iacovino M, Gilmore JM, Cox JL, Kyba M, Washburn MP, Rizzino A. Proteomic analysis of Sox2-associated proteins during early stages of mouse embryonic stem cell differentiation identifies Sox21 as a novel regulator of stem cell fate. Stem Cells 2010; 28:1715-27; PMID:20687156; http://dx.doi.org/10.1002/stem.494
45. Mallanna SK, Rizzino A. Emerging roles of microRNAs in the control of embryonic stem cells and the generation of induced pluripotent stem cells. Dev Biol 2010; 344:16-25; PMID:20478297; http://dx.doi.org/10.1016/j.ydbio.2010.05. 014
46. Telford WG, King LE, Fraker PJ. Evaluation of glucocorticoid-induced DNA fragmentation in mouse thymocytes by flow cytometry. Cell Prolif 1991; 24:447-59; PMID:1657218; http://dx.doi.org/10.1111/j.1365-2184.1991.tb01173.x